Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates CAMBRIDGE, Mass., November 5, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the third quarter ended September 30, 2026. "This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformat ...